Maxim Raises Target Price of Biotech Company
Source: Streetwise Reports
August 18, 2017 (Investorideas.com Newswire) A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech.
In an Aug. 8 research report, Maxim Group analyst Gabrielle Zhou noted the firm had raised its 12-month price target on CytoSorbents Corp. (CTSO:OTCBB) "to $12 from $10" due to the company "making steady progress on both commercial and clinical developments."
CytoSorbents "continues to drive the sales of CytoSorb in its launched territories and progress toward the initiation of CytoSorb's U.S. pivotal trial," Zhou wrote.
At the end of Q2/17, the company's blood purification therapy, CytoSorb, showed 17% sequential and 64% year-over-year growth, "mainly driven by the increase in direct sales from new customers and repeat orders (direct sales accounts for more than 67% of total product revenue)," Zhou explained. "While the company has not yet given guidance, management expects product sales in H2/17 will exceed the first half of the year."
CytoSorbents exited the quarter with "$16.4M in cash, which included a $5M debt facility with Bridge Bank. At the current burn rate, we estimate sufficient cash runway through 2018," indicated Zhou.
The analyst also provided an update on the company's U.S. REFRESH II study, which aims "to compare CytoSorb versus control in a large study (300–500 patients)." The trial "remains on track to initiate in H2/17," she said.
Also in the report, Zhou mentioned the use of CytoSorb in potentially increasing effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy. "While treatment with Tocilizumab (anti-IL6) and corticosteroids can help, a more attractive approach may be to filter out the cytokines with CytoSorb," she suggested. "If patients experiencing severe cytokine release syndrome can have cytokines filtered out of the blood and 'walked' down to a safer level that still promotes CAR-T efficacy, CytoSorb could be widely used by the CAR-T space, which is about to go commercial in 2018."
Maxim Group has a Buy rating and newly increased 12-month price target of $12 per share (up from $10 per share) on CytoSorbents Corp. Currently, the stock is trading at about $4.75 per share.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire http://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.